Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: TG6002

    Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

    Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

    Published 15 March 2023
    Categorized as 2023, dates, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

    Transgene announces Financial Calendar for 2023

    Transgene announces Financial Calendar for 2023 15

    Published 4 January 2023
    Categorized as 2023, dates, dates, Invir.IO, Press release, TG6002

    R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

    TRANSGENE R&D DAY

    Published 27 September 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

    Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

    2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

    Published 12 September 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Invir.IO, Press release, TG6002

    Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

    V. Moreno et al. ESMO 2022 Download the poster here Poster Presentation

    Published 11 September 2022
    Categorized as 2022, Publication, publication HP en, TG6002

    Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

    P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

    Published 23 September 2021
    Categorized as 2021, Publication, publication HP en, TG6002

    Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

    Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

    Published 16 September 2021
    Categorized as 2021, Invir.IO, Press release, TG6002, TG6002

    3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

    Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

    Published 1 July 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Publication, TG6002, TG6002

    Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

    K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

    Published 9 April 2021
    Categorized as 2021, Invir.IO, Publication, TG6002

    Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

    20210409 – TG6002 AACR EN

    Published 9 April 2021
    Categorized as 2021, Press release, TG6002, TG6002

    Posts navigation

    Page 1 … Page 3 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo